ProQR Therapeutics director Bart Filius buys $257,925 of common shares

• ProQR Therapeutics director Bart Filius bought 150,000 ordinary shares at USD 1.72 each.
• Holding rose to 300,000 ordinary shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProQR Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-085234), on July 21, 2026, and is solely responsible for the information contained therein.